Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance

August 30, 2024 updated by: National Human Genome Research Institute (NHGRI)

Where Culture Meets Genetics: Exploring Latinas' Causal Attributions of Breast and Colon Cancer and Mental Models of Disease Inheritance

Background:

Culture can affect the way a person thinks about illness. This can affect how they seek help for illness. It can also affect how they choose a treatment and follow it. This can lead to health disparities among certain groups of people. Breast and colon cancers are the most common cancers for Latinos. Even though they get these cancers at lower rates than other population groups, Latinos are more likely to be diagnosed with these cancers at advanced stages. Researchers want to study what Latina women immigrants believe causes breast and colon cancer and other factors they think play a role in disease. This understanding could lead to better interactions between Latinos and their doctors.

Objective:

To learn more about what Latina immigrants believe causes breast and colon cancer and other factors they think play a role in disease.

Eligibility:

Women ages 18 and older who:

Were born in Latin America

Speak Spanish

Have never had breast, ovarian, or colon cancer

Design:

Participants will be interviewed in person or over the phone. This will take up to an hour. The interview will be recorded. Participants will answer questions about:

Their family s cancer history

What they think causes breast and colon cancer

What they think plays a role in disease

...

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Research to understand the sources of health disparities has acknowledged that in addition to biomedical risk factors, culture plays an important role in differential health outcomes. Consequently, understanding cultural differences that may influence health behavior is key in working towards reducing these disparities. Causal attributions are a key component of individuals illness perceptions and thus impact health behaviors, which may present as health disparities at a population level. While research has explored non-Hispanic White women s causal attributions of breast cancer, less is known about Latina s beliefs about the causes of breast cancer, and little is known about causal attributions of colon cancer in any population. Understanding Latina s causal attributions of breast and colon cancer may provide insight into the determinants of cancer disparities in this population. Because a subset of both breast and colon cancers result from single gene mutations, which confer an increased risk of developing such cancers, understanding causal attributions in Latina populations is relevant to the field of genetics. This is especially true since Latinas have historically underutilized cancer genetic risk assessment counseling and testing services. As these services become a standard part of general healthcare provision, it will become increasingly important to understand ways in which different cultural groups interact with genetic information. One way this can be done is through investigating culturally informed mental models of disease risk and inheritance. This study seeks to describe causal attributions of breast and colon cancer and to explore mental models of disease inheritance among Latina immigrants . A qualitative exploratory design including interviews comprised of free-listing, ranking, and open-ended questions will be used. Participants will be recruited through the NIH Clinical Research Volunteer Program as well as using other resources within the Office of Participant Recruitment and from among individuals enrolled on other NIH Clinical Center protocols. First, we will describe Latina s causal attributions for these cancers. Next, we will use cultural consensus theory (CCT) to identify and describe common cultural models of causes of these cancers. Finally, we will explore Latina s mental models of disease inheritance using both free-listing and open-ended questions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
22

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Human Genome Research Institute (NHGRI)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Women who speak spanish as their primary language; living in the metropolitan Baltimore/Washington, DC region

Description

  • INCLUSION CRITERIA:
  • Are a woman, 18 years of age or older
  • Have immigrated to the United States from Latin America
  • Speak Spanish
  • Are able to meet in-person in the metro Washington, DC area

Puedes reunir los requisitos si:

  • Eres mujer y tienes 18 a(SqrRoot) os de edad o m(SqrRoot)(Degree)s
  • Has emigrado a los Estados Unidos desde Latinoam(SqrRoot)(Copyright)rica
  • Hablas el espa(SqrRoot) ol con fluidez
  • Puedes asistir en persona en la zona metropolitana de Washington, DC

EXCLUSION CRITERIA:

-NIH medical and research staff

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Spanish-speaking Latinas
Women who speak Spanish as their primary language

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
mental models of inheritance
Time Frame: baseline
qualitative descriptions of women's understanding/thoughts about inheritance
baseline
causal attributions of colon cancer
Time Frame: baseline
participants' free-lists of colon cancer causes
baseline
causal attributions of breast cancer
Time Frame: baseline
participants' free-lists of breast cancer causes
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Human Genome Research Institute (NHGRI)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Lori Erby, Ph.D., National Human Genome Research Institute (NHGRI)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 10, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 2, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 2, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 10, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 10, 2016

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 11, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 3, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 30, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 999916106
  • 16-HG-N106

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings